Skip to main content

Risk for Second Primary Cancer May Be No Higher With CAR T-Cell Versus Standard of Care

Medically reviewed by Carmen Pope, BPharm. Last updated on Sep 12, 2024.

By Elana Gotkine HealthDay Reporter

THURSDAY, Sept. 12, 2024 -- The overall second primary malignancy (SPM) point estimate was 5.8 percent for patients receiving chimeric antigen receptor (CAR) T-cell therapy, according to a study published online Sept. 11 in Clinical Cancer Research.

Tobias Tix, from LMU Klinikum in Munich, and colleagues conducted a systematic review to delineate the frequency and subtypes of SPMs following CAR T-cell therapy in lymphoma and myeloma. A total of 326 SPMs were identified across 5,517 patients from 18 clinical trials and seven real-world studies.

The researchers found that the overall SPM point estimate was 5.8 percent with a median follow-up of 21.7 months. There were associations for SPM estimates with treatment setting (clinical trials > real-world settings), follow-up duration, and number of previous treatment lines. In a meta-regression model, these associations were confirmed as independent study-level risk factors for SPM. The risk for SPM was similar with either treatment strategy in a subgroup meta-analysis of four trials that randomly assigned patients to CAR T-cell therapy versus standard of care. In an analysis of SPM subtypes, the most common were hematologic malignancies, followed by solid tumors and nonmelanoma skin cancers (37, 27, and 16 percent, respectively). A small minority of events were T-cell malignancies (1.5 percent).

"By understanding the factors contributing to SPM development and implementing effective monitoring strategies, health care providers can optimize patient outcomes and ensure the long-term safety of CAR T-cell therapies," the authors write.

Several authors disclosed ties to the pharmaceutical industry.

Abstract/Full Text (subscription or payment may be required)

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

© 2025 HealthDay. All rights reserved.

Posted September 2024

Read this next

Childhood Cancer Survivors Have Increased Risk for CKD, Hypertension

THURSDAY, May 22, 2025 -- Childhood cancer survivors (CCS) have an increased risk for chronic kidney disease (CKD) and hypertension, according to a study published online May 19...

Testosterone Use Not Tied to Gynecological Cancers in Transmasculine Individuals

FRIDAY, May 16, 2025 -- Short-term testosterone use among transmasculine and gender diverse (TMGD) individuals is not associated with an increased risk for gynecological cancers...

Increases in Incidence Rates of Some Cancers Seen in Early-Onset Age Groups

THURSDAY, May 15, 2025 -- The incidence rates of 14 cancers have increased in early-onset age groups, with increases in older-onset age groups also occurring in most of these...

More news resources

Subscribe to our newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.